Critical Role for AMPK in Metabolic Disease-Induced Chronic Kidney Disease

Florian Juszczak1,2, Nathalie Caron2, Anna V Mathew3

  • 1Laboratory of Molecular and Metabolic Biochemistry, Faculty of Medicine and Pharmacy, Research Institute for Health Sciences and Technology, University of Mons (UMONS), 7000 Mons, Belgium.

Insights

AMP-activated protein kinase (AMPK) is crucial for kidney health, regulating metabolism and cell survival. Activating AMPK may offer new therapeutic strategies for chronic kidney disease (CKD) linked to metabolic disorders.

Area of Science:

  • Nephrology
  • Metabolic Diseases
  • Molecular Biology

Background:

  • Chronic kidney disease (CKD) affects 9.1% globally, posing significant health risks.
  • Metabolic disturbances like obesity and diabetes are key risk factors and contributors to CKD.
  • AMP-activated protein kinase (AMPK) is vital for cellular energy balance and is expressed in kidney podocytes and proximal tubular cells.

Purpose of the Study:

  • To review the critical role of AMPK in renal cell dysfunction in metabolic disease-related CKD.
  • To explore AMPK's function in kidney autophagy and mitochondrial quality control.
  • To identify potential therapeutic strategies targeting AMPK for CKD.

Main Methods:

  • Literature review focusing on AMPK's role in metabolic disease-induced kidney dysfunction.
  • Analysis of studies investigating AMPK's impact on renal cell metabolism, survival, and autophagy.
  • Synthesis of current understanding of AMPK in CKD pathogenesis.

Main Results:

  • AMPK activation ameliorates pathological features in obesity-related and diabetic CKD.
  • AMPK acts as a metabolic sensor, regulating tubular transport and cellular energy states.
  • AMPK is essential for mitochondrial homeostasis and autophagy in mammalian cells.

Conclusions:

  • Dysregulated AMPK in the kidney is implicated in metabolic disease-related CKD.
  • Further investigation into AMPK's role in autophagy and mitochondrial quality control is needed.
  • Understanding AMPK's mechanisms can lead to novel therapeutic approaches for CKD.

Related Concept Videos

Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
383
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
7.5K
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
231
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.9K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
389
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
90